The combination of atezolizumab (anti-PD-L1 mAb) with nab-paclitaxel was the first such immunotherapy treatment approved for breast cancer, demonstrating a significant progression-free survival advantage in patients with PD-L1-positive metastatic NTBC [60]. Here, CD274 is linked to breast carcinoma.